Zhitong Finance App News, Microchip Biotech (688321.SH) issued an announcement. The company recently received the “Drug Clinical Trial Approval Notice” issued by the State Drug Administration, agreeing to conduct clinical trials for acute myeloid leukemia with the company's product CS43158 tablets. CS43158 is a multi-target protein kinase inhibitor that can simultaneously cover both the driving carcinogenic pathway and the bypass activation drug resistance pathway in acute myeloid leukemia (AML), and has the dual effect of targeting primary driver mutations and overcoming secondary drug resistance.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.